Cyclerion Therapeutics (CYCN) Non Operating Income (2020 - 2025)
Cyclerion Therapeutics (CYCN) posted quarterly Non Operating Income of $30000.0 for Q3 2025, down 92.59% year-over-year from $405000.0 in Q3 2024, and down 97.77% quarter-over-quarter from $1.3 million in Q2 2025.
Cyclerion Therapeutics (CYCN) Non Operating Income (2020 - 2025) Analysis & Trends
Cyclerion Therapeutics' Non Operating Income history runs 6 years deep, the most recent figure standing at $30000.0 for Q3 2025.
- In Q3 2025, Non Operating Income fell 92.59% year-over-year to $30000.0; the TTM figure through Sep 2025 stood at $1.4 million (up 122.67% YoY), while the FY2024 annual figure was $571000.0, up 59.5% from the prior year.
- Non Operating Income for Q3 2025 stood at $30000.0, down from $1.3 million in the prior quarter.
- The five-year high for Non Operating Income was $1.3 million in Q2 2025, with the low at -$6000.0 in Q2 2021.
- The 5-year median for Non Operating Income is $62000.0 (2023), against an average of $137526.3.
- The sharpest annual moves came in 2021 and 2022: Non Operating Income slumped 105.38% in 2021, then jumped 13300.0% in 2022.
- Cyclerion Therapeutics' Non Operating Income stood at -$1000.0 in 2021, then surged by 13300.0% to $132000.0 in 2022, then fell by 23.48% to $101000.0 in 2023, then plunged by 72.28% to $28000.0 in 2024, then increased by 7.14% to $30000.0 in 2025.
- Business Quant data shows CYCN's Non Operating Income at $30000.0 in Q3 2025, $1.3 million in Q2 2025, and $28000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Cyclerion Therapeutics | 12.71 Mn | 9.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 30,000.00 |
| Jun 30, 2025 | 1.35 Mn |
| Mar 31, 2025 | 28,000.00 |
| Dec 31, 2024 | 28,000.00 |
| Sep 30, 2024 | 405,000.00 |
| Jun 30, 2024 | 62,000.00 |
| Mar 31, 2024 | 76,000.00 |
| Dec 31, 2023 | 101,000.00 |
| Sep 30, 2023 | 107,000.00 |
| Jun 30, 2023 | 62,000.00 |
| Mar 31, 2023 | 88,000.00 |
| Dec 31, 2022 | 132,000.00 |
| Sep 30, 2022 | 111,000.00 |
| Jun 30, 2022 | 45,000.00 |
| Mar 31, 2022 | 6,000.00 |
| Dec 31, 2021 | -1,000.00 |
| Sep 30, 2021 | -5,000.00 |
| Jun 30, 2021 | -6,000.00 |
| Mar 31, 2021 | -4,000.00 |
| Dec 31, 2020 | -4,000.00 |